ovispirin-1

General Information


DRACP ID  DRACP00020

Peptide Name   ovispirin-1

Sequence  KNLRRIIRKIIHIIKKYG

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
ME-180 Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri Carcinoma 100% Cytotoxicity=200 µg/ml MTT assay 20h 1
A549 Lung adenocarcinoma Carcinoma 99.7% Cytotoxicity=200 µg/ml MTT assay 20h 1

Hemolytic Activity  Human erythrocytes: 70% Hemolysis=80 µg/ml

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00020

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C105H188N34O21

Absent amino acids  ACDEFMPQSTVW

Common amino acids  I

Mass  256628

Pl  12.28

Basic residues  8

Acidic residues  0

Hydrophobic residues  7

Net charge  8

Boman Index  -4302

Hydrophobicity  -37.22

Aliphatic Index  151.67

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  87.65

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 11932493

Title  Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides

Doi 10.1093/protein/15.3.225

Year  2002

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.